Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 701 to 725 of 881

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Bortezomib for previously untreated mantle cell lymphoma	TA370	16 December 2015	16 December 2015
Ledipasvir–sofosbuvir for treating chronic hepatitis C	TA363	25 November 2015	25 November 2015
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C	TA365	25 November 2015	25 November 2015
Vortioxetine for treating major depressive episodes	TA367	25 November 2015	25 November 2015
Tolvaptan for treating autosomal dominant polycystic kidney disease	TA358	28 October 2015	28 October 2015
Idelalisib for treating chronic lymphocytic leukaemia	TA359	28 October 2015	28 October 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)	TA362	28 October 2015	28 October 2015
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	TA352	26 August 2015	26 August 2015
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	TA353	26 August 2015	26 August 2015
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	TA354	26 August 2015	26 August 2015
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)	TA351	22 July 2015	22 July 2015
Naloxegol for treating opioid‑induced constipation	TA345	22 July 2015	22 July 2015
Aflibercept for treating diabetic macular oedema	TA346	22 July 2015	22 July 2015
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer	TA347	22 July 2015	22 July 2015
Everolimus for preventing organ rejection in liver transplantation	TA348	22 July 2015	22 July 2015
Secukinumab for treating moderate to severe plaque psoriasis	TA350	22 July 2015	22 July 2015
Omalizumab for previously treated chronic spontaneous urticaria	TA339	8 June 2015	8 June 2015
Vedolizumab for treating moderately to severely active ulcerative colitis	TA342	5 June 2015	5 June 2015
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	TA341	4 June 2015	4 June 2015
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia	TA343	2 June 2015	2 June 2015
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome	TA335	25 March 2015	25 March 2015
Empagliflozin in combination therapy for treating type 2 diabetes	TA336	25 March 2015	25 March 2015
Rifaximin for preventing episodes of overt hepatic encephalopathy	TA337	25 March 2015	25 March 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)	TA334	25 February 2015	25 February 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy	TA329	25 February 2015	25 February 2015

Results per page

10
25
50
All